- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00918086
Impact of Vitamin D Supplementation on Host Immunity to Mycobacterium Tuberculosis and Response to Treatment
Impact of Vitamin D Supplementation on Host Immunity to Mycobacterium Tuberculosis and Response to Treatment: Building Translational Research Capacity in Nutrition and Infectious Diseases in the Republic of Georgia
Tuberculosis bacterium (TB) is a germ that can infect any part of the human body, especially the lungs. Vitamin D is a hormone present in humans that regulates blood electrolytes such as calcium and phosphate. There is new information that links vitamin D to the functioning of our immune system. The purpose of the study is to find out how vitamin D affects the immune system of patients with TB. We want to find out if correcting low vitamin D levels, in addition to getting standard therapy for TB, will help the immune system fight off TB infection more effectively.
The study will be done at the Georgia National Center for Tuberculosis and Lung Diseases (NCTBLD) in Tbilisi, Republic of Georgia. 220 patients with tuberculosis and 80 family members or household contacts of patients with tuberculosis will be participating in this study. TB patients, already receiving standard TB therapy, will be randomly assigned to either receive the Vitamin D pill or a placebo for a total of sixteen weeks. Neither the subject nor the investigator will know whether the subject has received the Vitamin D or the inactive placebo.The subject will orally consume the Vitamin D/placebo tablet 3 times a week for the 1st 8 weeks (while in hospital) and then once every other week for the last 8 weeks( during out-patient visits to the hospital).
The main study hypothesis is that Vitamin D supplementation helps patients with tuberculosis, who are on standard anti TB antibiotic therapy, get better faster.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This is a double-blind, randomized, controlled clinical trial on the clinical efficacy and antimicrobial mechanisms of oral high dose vitamin D3 therapy three times weekly given for 8 weeks followed by the same vitamin D dose given every other week for a subsequent 8 weeks (n=129) versus placebo (n=129) in newly diagnosed Georgian patients with pulmonary TB.
The trial is also designed to obtain needed information on vitamin D status and general nutritional status in TB patients in Georgia, explore vitamin D regulation of the endogenous antimicrobial peptide cathelicidin/LL-37 in human tissues, and obtain hypothesis-generating data on the potential role of cathelicidin/LL-37 as a mechanism for the anti-mycobacterial effects of vitamin D in humans.
The potential study subjects will be identified and clinically monitored by clinical study coordinators after diagnosis by standard methods (compatible signs and symptoms, positive sputum AFB smear and culture, chest X-ray). Medical records of all patients with newly diagnosed tuberculosis registered for treatment at the NCTBLD in Tbilisi will be screened for eligibility for participation in the study. Written informed consent will be obtained from patients who met eligibility criteria and agreed to participate in the study prior to the subject undergoing any study-related procedure. Participation in study will involve a total of seven study visits (one baseline and six follow up visits.
TB patients will otherwise be conventionally treated with anti-TB drug regimens using the DOTS protocols: an initial 2 month in-hospital intensive phase with daily treatment with oral rifampicin, isoniazid, pyrazinamide and ethambutol, followed by an outpatient continuation phase for 4 months with rifampicin and isoniazid only, given 3 times per week. Given data that TB disease itself is associated with vitamin D depletion we will also recruit 80 otherwise healthy, adult family members of the pulmonary TB patients as a pilot substudy. Family members recruited will be those accompanying the TB patient to clinic.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Tbilisi, Georgia, 0101
- National Center for Tuberculosis and Lung Diseases
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patient is age > 18 years;
- Patient has documented new case of smear-positive pulmonary TB;
- Patient has received ≤ 1 week of anti-TB therapy;
- The patient will receive anti-TB therapy in Tbilisi;
- Patient has provided informed consent.
Exclusion Criteria:
- Patient has had > 30 days of lifetime TB therapy;
- Patient is currently pregnant or lactating;
- Patient has a history of organ transplant;
- Patient has a history of cancer in past 5 years (ineligibility criteria does not include non-melanoma skin cancer);
- Patient has a history of seizures;
- Patient has a history of hypercalcemia;
- Patient has a history of hyperparathyroidism;
- Patient has a history of sarcoidosis;
- Patient has a history of nephrolithiasis (renal stones);
- Patient has taken oral corticosteroids in the past 30 days;
- Patient is currently using cytotoxic or immunosuppressive drugs;
- Patient currently has significant renal dysfunction (defined as a serum creatinine of >250mmol/L);
- Patient requires dialysis therapy;
- Patient has a history of cirrhosis;
- Patient is currently incarcerated;
- Patient is not able to complete all study visits in at the NCTBLD in Tbilisi.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador de placebos: Placebo
|
An inactive pill that looks and tastes like the Vitamin D pill
|
Experimental: Vitamin D pill
|
Oral tablet taken for 16 weeks
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
The primary outcome for this intent-to-treat trial is the time to Mycobacterium tuberculosis sputum culture conversion to negative
Periodo de tiempo: Up to 16 weeks from therapy start date
|
Up to 16 weeks from therapy start date
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
Sputum culture result (positive or negative)
Periodo de tiempo: 8 weeks after therapy start date
|
8 weeks after therapy start date
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Infecciones
- Infecciones bacterianas
- Infecciones bacterianas y micosis
- Infecciones por bacterias grampositivas
- Infecciones por Actinomycetales
- Infecciones por micobacterias
- Tuberculosis
- Efectos fisiológicos de las drogas
- Micronutrientes
- Vitaminas
- Agentes de conservación de la densidad ósea
- Vitamina D
Otros números de identificación del estudio
- IRB00014641
- Vitamin D Georgia Study (Otro identificador: Other)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Tuberculosis
-
Assistance Publique - Hôpitaux de ParisTerminadoTuberculosis extrapulmonar | Tuberculosis de los ganglios linfáticos | Tuberculosis óseaFrancia
-
Wits Health Consortium (Pty) LtdUniversity of Cape Town; Perinatal HIV Research Unit of the University of the... y otros colaboradoresActivo, no reclutandoTuberculosis | Tuberculosis multirresistente | Tuberculosis resistente a la rifampicina | Tuberculosis extremadamente resistente a los medicamentos | Pre-TB-XDRSudáfrica
-
Huashan HospitalShanghai First Maternity and Infant HospitalDesconocidoInfertilidad Femenina | Fallo de implantación recurrente | Tuberculosis Genital Femenina | Tuberculosis Genital, LatentePorcelana
-
Global Alliance for TB Drug DevelopmentTerminadoTuberculosis | Tuberculosis Pulmonar | Enfermedad pulmonar | Tuberculosis multirresistente | Tuberculosis sensible a fármacos | Tuberculosis resistente a los medicamentos | Infección por Mycobacterium TuberculosisEstados Unidos
-
Global Alliance for TB Drug DevelopmentTerminadoTuberculosis | Tuberculosis Pulmonar | Enfermedad pulmonar | Tuberculosis multirresistente | Tuberculosis sensible a fármacos | Tuberculosis resistente a los medicamentos | Infección por Mycobacterium TuberculosisEstados Unidos
-
Medecins Sans Frontieres, NetherlandsLondon School of Hygiene and Tropical Medicine; University of Liverpool; Ministry... y otros colaboradoresTerminadoTuberculosis multirresistente | Tuberculosis Pulmonar | Tuberculosis extremadamente resistente a los medicamentosBielorrusia, Sudáfrica, Uzbekistán
-
Johns Hopkins UniversityUnited States Agency for International Development (USAID)Aún no reclutandoTuberculosis | Tuberculosis Pulmonar | Tuberculosis micobacteriana | Tuberculosis, Nódulo LinfáticoUganda, Sudáfrica, Mozambique, Indonesia, Zambia
-
University Medical Center GroningenTerminadoTuberculosis multirresistente | Tuberculosis extremadamente resistente a los medicamentosPaíses Bajos
-
Medecins Sans Frontieres, NetherlandsLondon School of Hygiene and Tropical Medicine; University College, London; University... y otros colaboradoresActivo, no reclutandoTuberculosis multirresistente | Tuberculosis pulmonar | Tuberculosis extremadamente resistente a los medicamentosBielorrusia, Sudáfrica
-
University of Cape TownInstitute of Tropical Medicine, Belgium; Epicentre; Medecins Sans Frontieres, Netherlands y otros colaboradoresReclutamientoTuberculosis multirresistenteVietnam, Kazajstán, Lesoto, Pakistán, Perú, Sudáfrica
Ensayos clínicos sobre Vitamin D pill
-
Aalborg UniversityAalborg University Hospital; CCBR Aalborg A/S, Aalborg, DenmarkTerminadoMigraña según los criterios de la International Headache Society (IHS) (ICHD-II)Dinamarca
-
Wake Forest University Health SciencesWorld Health Organization; National Hospital of Sri LankaTerminado
-
Royal Prince Alfred Hospital, Sydney, AustraliaTerminadoColonoscopiaAustralia
-
Rhode Island HospitalVirtually Better, Inc.TerminadoSalud mental | Virus de inmunodeficiencia humanaEstados Unidos
-
GlaxoSmithKlineTerminadoInfluenza HumanaEstados Unidos, Bélgica
-
Johns Hopkins UniversityNational Institute of Allergy and Infectious Diseases (NIAID)Reclutamiento
-
University Medical Center GroningenMaastricht University Medical Center; UMC Utrecht; Academisch Medisch Centrum -... y otros colaboradoresTerminadoInsuficiencia cardiacaPaíses Bajos
-
Daewoong Pharmaceutical Co. LTD.Aún no reclutando
-
University of AarhusNovo Nordisk A/S; Aarhus University Hospital; AP Moeller Foundation; Danish Diabetes...ReclutamientoEnvejecimiento | Trastorno del metabolismo | Cetonemia | Trastorno muscularDinamarca
-
Heartseed Inc.ReclutamientoInsuficiencia cardiaca | Enfermedad isquémica del corazónJapón